AZD9291

Known as: 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, AZD-9291 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
0204020142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
PURPOSE Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR… (More)
  • figure 1
  • table 1
  • table 2
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
OBJECTIVES To assess the ability of different technology platforms to detect epidermal growth factor receptor (EGFR) mutations… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 4
Is this relevant?
2015
2015
BACKGROUND AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers. Early identification of innate or… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2015
2015
INTRODUCTION AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
UNLABELLED First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical benefit in patients with… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
The first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in advanced non-small… (More)
Is this relevant?
2014
2014
Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer… (More)
Is this relevant?